Market Access After COVID-19: Sector Goodwill Or Hard Crackdown?

The pandemic has brightened pharma’s image, but drug pricing is still high on the political agenda. For US and European politicians, the health crisis has heightened the tension between supporting innovation and controlling rising costs.